Crossject: renewed cooperation with the Pentagon

(CercleFinance.com) - Crossject announced on Monday that it has relaunched its cooperation with the US Department of Defense on research into needle-free auto-injectors.


The pharmaceutical company has signed an extension to the research and development (R&D) agreement it originally signed in October 2019 with the Pentagon to evaluate an enhanced version of its needle-free auto-injector.

The company says the agreement with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRN) aims to offer military personnel and first responders 'an immediate, reliable and easy-to-use solution for administering life-saving treatment in the most extreme and dangerous conditions'.

Crossject's technology is designed to enable easy and instantaneous administration of emergency medication by intramuscular injection on bare skin or through clothing, for example in cases of allergic shock and adrenal insufficiency.

Following this announcement, Crossject's share price climbed by over 8% on the Paris Bourse on Monday morning, although this has not prevented it from posting a 58% decline this year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.